Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XFOR - X4 Pharmaceuticals, Inc

IEX Last Trade
0.7055
0   0%

Share volume: 0
Last Updated: Fri 20 Dec 2024 09:18:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.46%

PREVIOUS CLOSE
CHG
CHG%
$0.71
-0.04
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 8%
Dept financing 8%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-17.25%
1 Month
80.86%
3 Months
-13.43%
6 Months
-39.48%
1 Year
-15.50%
2 Year
-27.46%
Key data
Stock price
$0.71
P/E Ratio 
0.00
DAY RANGE
$0.67 - $0.71
EPS 
$0.00
52 WEEK RANGE
$0.36 - $1.60
52 WEEK CHANGE
-$15.50
MARKET CAP 
117.950 M
YIELD 
N/A
SHARES OUTSTANDING 
168.500 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.49
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,101,789
AVERAGE 30 VOLUME 
$3,385,596
Company detail
CEO: Paula S. Ragan
Region: US
Website: x4pharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.

Recent news